x

Posted 28 April, 2023

Senti Biosciences, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:SNTI in a 8-K filed on 28 April, 2023.


  On April 26, 2023, Mr. David R. Epstein, informed the board of directors (the "Board") of Senti Biosciences, Inc. ("Senti") of his intention to resign as a director of Senti, including resignation from all the committees of the Board on which he serves, effective as of the close of business on June 16, 2023. Mr. Epstein has resigned in order to minimize potential conflict or the appearance of conflict with his role as Chief Executive Officer of Seagen, Inc. (an oncology company) rather than because of any disagreement relating to any of Senti's operations, policies or practices.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Senti Biosciences, Inc.
Health Care/Life Sciences • Biotechnology
Senti Biosciences, Inc. is a biotechnology company. It engages in the business of developing next-generation cell and gene therapies engineered with a gene circuit platform technology to fight challenging diseases. The company was founded by Timothy K. Lu, Wilson Wong, and Philip Lee on June 9, 2016 and is headquartered in South San Francisco, CA.
Market Cap
$15.3M
View Company Details
Senti Biosciences, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(a)


On April 26, 2023, Mr. David R. Epstein, informed the board of directors (the "Board") of Senti Biosciences, Inc. ("Senti") of his intention to resign as a director of Senti, including resignation from all the committees of the Board on which he serves, effective as of the close of business on June 16, 2023. Mr. Epstein has resigned in order to minimize potential conflict or the appearance of conflict with his role as Chief Executive Officer of Seagen, Inc. (an oncology company) rather than because of any disagreement relating to any of Senti's operations, policies or practices. He has expressed his support for Senti's mission to transform cell and gene therapies with gene circuits going forward. Senti would like to thank Mr. Epstein for his contributions and service on its Board.